PDCD1 and hepatocellular carcinoma: A randomized, open and controlled multicenter phase III clinical study (NCT04720716) aims to test the effectiveness of the combination of IBI310 (anti-CTLA-4 monoclonal antibody) combined with the PD-1 inhibitor sintilimab for the first-line treatment of advanced HCC is also ongoing.